Physician profile
Feiyu Chen
NPI 1912997990
$3,853.67
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,154 · 2020: $562 · 2021: $35.12 · 2022: $34.48 · 2023: $68.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $68.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $68.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $453.74 | 2019-2020 | |
| Lundbeck LLC | $271.33 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $268.02 | 2019-2020 | |
| Allergan, INC. | $253.28 | 2019-2021 | |
| Akcea Therapeutics, INC. | $221.38 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $211.90 | 2019-2022 | |
| Abbvie INC. | $197.44 | 2019-2023 | Botox |
| Lilly USA, LLC | $183.75 | 2019-2023 | Emgality, Reyvow |
| Biogen, INC. | $179.24 | 2019-2020 | |
| Amgen INC. | $171.59 | 2019-2020 | |
| Genentech USA, INC. | $163.05 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $159.87 | 2019 | |
| Emd Serono, INC. | $152.05 | 2019 | |
| Avanir Pharmaceuticals, INC. | $121.52 | 2019 | |
| Supernus Pharmaceuticals, INC. | $112.49 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $94.93 | 2019 | |
| Acadia Pharmaceuticals INC | $80.32 | 2019 | |
| Assertio Therapeutics, INC. | $64.11 | 2019 | |
| Eisai INC. | $61.69 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $61.15 | 2019-2020 | |
| Tanabe Pharma America, INC. | $47.58 | 2019-2020 | |
| Genzyme Corporation | $47.13 | 2019 | |
| Csl Behring | $46.40 | 2019-2020 | |
| Pfizer INC. | $40.14 | 2019 | |
| Zyla Life Sciences, INC. | $32.76 | 2019-2020 | |
| Ucb, INC. | $31.83 | 2019-2020 | |
| Ge Healthcare | $29.53 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $18.72 | 2019 | |
| Sk Life Science, INC. | $17.79 | 2020 | |
| Impel Pharmaceuticals INC. | $16.70 | 2022 | |
| Acorda Therapeutics, INC | $14.85 | 2019 | |
| Upsher-Smith Laboratories LLC | $14.78 | 2020 | |
| Harmony Biosciences LLC | $12.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feiyu Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.